Abstract
The first proteolytic step in the processing of amyloid precursor protein (APP) to amyloid-beta (Aβ) in the brain is performed by β-site APP cleaving enzyme (BACE1). This enzyme is a membrane bound aspartic protease with high homology of the catalytic domain to renin and pepsin and of yet unknown physiologic function. It is a primary drug discovery target for Alzheimers disease therapy. The first potent inhibitors are based on the sequence of APP around the β-secretase cleavage site EVNL / DAEF, with the scissile Leu-Asp amide bond being replaced by a hydroxyethylene transition state analogue isostere. In addition, lipophilic sidechains have been incorporated and a crystal structure of such an octapeptidic inhibitor bound in the active site is already available. Recent progress in the field of BACE inhibition is reviewed.
Keywords: bace, aspartic protease, inhibition, app, amyliod, pepstatin, protease, indinavir, amprenavir, tipranavir, aliskiren
Current Topics in Medicinal Chemistry
Title: Inhibition of BACE, a Promising Approach to Alzheimers Disease Therapy
Volume: 2 Issue: 4
Author(s): Silvio Roggo
Affiliation:
Keywords: bace, aspartic protease, inhibition, app, amyliod, pepstatin, protease, indinavir, amprenavir, tipranavir, aliskiren
Abstract: The first proteolytic step in the processing of amyloid precursor protein (APP) to amyloid-beta (Aβ) in the brain is performed by β-site APP cleaving enzyme (BACE1). This enzyme is a membrane bound aspartic protease with high homology of the catalytic domain to renin and pepsin and of yet unknown physiologic function. It is a primary drug discovery target for Alzheimers disease therapy. The first potent inhibitors are based on the sequence of APP around the β-secretase cleavage site EVNL / DAEF, with the scissile Leu-Asp amide bond being replaced by a hydroxyethylene transition state analogue isostere. In addition, lipophilic sidechains have been incorporated and a crystal structure of such an octapeptidic inhibitor bound in the active site is already available. Recent progress in the field of BACE inhibition is reviewed.
Export Options
About this article
Cite this article as:
Roggo Silvio, Inhibition of BACE, a Promising Approach to Alzheimers Disease Therapy, Current Topics in Medicinal Chemistry 2002; 2 (4) . https://dx.doi.org/10.2174/1568026024607490
DOI https://dx.doi.org/10.2174/1568026024607490 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Non-Antidepressant Long-term Treatment in Post-Traumatic Stress Disorder (PTSD)
Current Clinical Pharmacology TGF-β2 Signaling in High-Grade Gliomas
Current Pharmaceutical Biotechnology Species Scaling and Extrapolation
Current Drug Metabolism The Impact of Antidepressant-Associated Sexual Dysfunction on Treatment Adherence in Patients with Major Depressive Disorder
Current Psychiatry Reviews An Update on the Role of Matrix Metalloproteinases in the Pathogenesis of Multiple Sclerosis
Medicinal Chemistry Hypertension in Older Patients
Current Hypertension Reviews Complementary and Alternative Medicine Usage and Its Determinant Factors Among Infertile Women: A Case of Iran
Current Traditional Medicine Computational Challenges of Personal Genomics
Current Genomics Editorial: Generation Rx: Adolescent Prescription Drug Abuse
Current Drug Abuse Reviews From Cerebrospinal Fluid Pulsation to Noninvasive Intracranial Compliance and Pressure Measured by MRI Flow Studies
Current Medical Imaging Harnessing Stem Cells and Neurotrophic Factors with Novel Technologies in the Treatment of Parkinson’s Disease
Current Stem Cell Research & Therapy The Double-Edged Nature of Recovery in First-Episode Psychosis
Current Psychiatry Reviews Towards Alzheimers Disease Vaccination
Mini-Reviews in Medicinal Chemistry Schizophrenia: From Dopamine to Glutamate and Back
Current Medicinal Chemistry Treatment of Alzheimers Disease: The Beginning of a New Era Dale Schenk, ISOA - October 5th-6th, 2005
Current Alzheimer Research Intramolecular Processes and Their Applications in Prodrugs Approaches- Experimental and Computational Studies
Current Organic Chemistry Prostaglandin E<sub>2</sub> Receptor 4 (EP4): A Promising Therapeutic Target for the Treatment of Cancer and Inflammatory Diseases
Current Chemical Biology Monocyclic and Fused Azines and Azoles as Histamine H<sub>4</sub> Receptor Ligands
Current Medicinal Chemistry Review: New Anti-Cytokines for IBD: What is in the Pipeline?
Current Drug Targets Neuroendocrine Response to Psychosocial Stressors, Inflammation Mediators and Brain-periphery Pathways of Adaptation
Central Nervous System Agents in Medicinal Chemistry